Clinical Trials Logo

Gut Microbiomes clinical trials

View clinical trials related to Gut Microbiomes.

Filter by:
  • None
  • Page 1

NCT ID: NCT04533724 Not yet recruiting - Schizophrenia Clinical Trials

Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia

Start date: October 1, 2020
Phase: Early Phase 1
Study type: Interventional

Negative symptoms are one of the five-dimensional symptoms of patients with schizophrenia, and medications are not effective in treating negative symptoms. The mechanism of negative symptoms of schizophrenia is unknown, which may be related to insufficient dopamine function of the prefrontal cortex. Amisulpride is a D2/D3 receptor antagonist, which can improve negative symptoms. Intestinal microbes are related to central nervous system mental diseases. Animal studies have found that changes in the intestinal microflora are related to schizophrenia. Clinical studies have found that the gut microbes of patients with schizophrenia are different from those of normal healthy people. Therefore, we are trying to discover the changes of gut microbes in patients with effective amisulpride treatment, and to improve the negative symptoms of schizophrenia patients through the intestinal immune system. The mechanism of brain relationship provides direction, and also provides a new way for the drug treatment of negative symptoms.